DuPont releases E-Guide on PPE for pharmaceutical applications

14-Dec-2022

The guide examines how to protect workers against hazardous substances and prevent contamination in vaccine manufacturing and oncology drug production

DuPont releases E-Guide on PPE for pharmaceutical applications

DuPont has released a new e-guide on how to protect workers while maintaining the highest level of cleanliness in critical, rapidly-evolving pharmaceutical applications. The guide helps HSE managers so they can select the most appropriate Personal Protective Equipment (PPE) for vaccine and oncology drugs manufacturing.

Novel diseases, the development of innovative medical treatments, and new regulations are setting new requirements for essential PPE such as protective garments. For example, HSE managers now must ensure compliance with the recently-updated Directive 2004/37/EC on carcinogens, mutagens, and reprotoxic (CMR) substances and the final version of EU's Good Manufacturing Practice (GMP) Annex 1 guideline for cleanroom garments. 

DuPont’s guide shines new light on how the latest protective garment technology can help protect workers against emerging risks in fast-growing industries like vaccine manufacturing and oncology drug production and preparation. The guide also examines key steps to avoiding contamination in such applications, to uphold the quality of medicinal products. 

Selecting high-quality PPE that delivers optimal protection and comfort is essential; this is where our new e-guide comes in to help

‘‘Keeping workers safe while minimising the risk of environmental contamination is a top priority in the pharmaceutical industry,” said Steve Marnach, EMEA Training manager & Specialist Critical Environments at DuPont Personal Protection. “Selecting high-quality PPE that delivers optimal protection and comfort is essential; this is where our new e-guide comes in to help’’.

Sign up for your free email newsletter

After examining the key regulations and standards to be aware of, the guide looks at the key factors to consider when selecting protective garments to address specific risks and challenges in vaccine manufacturing and oncology drug production.

Companies